Primary aldosteronism: a new understanding.
Primary aldosteronism (PAL) may always have a genetic basis. This leads to either abnormally regulated, increased biosynthesis (Familial Hyperaldosteronism Type I, FHI) or to unrestrained hyperplasia and neoplasia, usually benign. The distinction between diffuse hyperplasia, nodular hyperplasia and adenoma may be relatively unimportant in functional and etiological terms. The genetic basis must be understood before diagnosis of disease (FHI) or of predisposition (all other PAL) can be made at birth and appropriate surveillance commenced. The natural history of PAL other than FHI is for progressive increase in severity, with both adrenals eventually involved. Long-term follow-up of PAL is therefore mandatory, and postoperative assessment of residual non-suppressible aldosterone production by fludrocortisone suppression testing useful in defining biochemical cure or improvement, and the need for specific medical treatment.
Gordon
R D
RD
Hypertension Unit, Greenslopes Hospital, Brisbane, Australia.
D000306:Adrenal Cortex Neoplasms / Q000209:etiology / Q000235:genetics / Q000503:physiopathology; D005260:Female; D005938:Glucocorticoids; D006801:Humans; D006929:Hyperaldosteronism / Q000175:diagnosis / Q000235:genetics* / Q000503:physiopathology; D007231:Infant, Newborn; D008297:Male; D009154:Mutation; D011379:Prognosis; D012084:Renin-Angiotensin System / Q000502:physiology
D005938:Glucocorticoids